{"groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"FG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"18"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"76"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"30"}],"type":"Participants refused further follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"15"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Enrolled but not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"309"},{"groupId":"FG001","numSubjects":"306"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"309"},{"groupId":"FG001","numSubjects":"306"}],"comment":"All randomized participants, who received study drug/a different drug to which they were randomized","type":"Intent-to-Treat Population"},{"achievements":[{"comment":"3 were randomized but not treated: 2 refused treatment \\& 1 withdrew before receiving study drug","groupId":"FG000","numSubjects":"306"},{"comment":"2 were randomized but not treated: 1 was screening failure \\& 1 discontinued due to new liver lesions","groupId":"FG001","numSubjects":"304"}],"comment":"All participants, who received at least 1 dose of study drug according to actual study treatment","type":"As-Treated Population"},{"achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"165"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"141"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Screening: From Week 0 (nephrectomy surgery) to Week 11; in this period, echocardiogram/multi-gated acquisition, post-surgery imaging, histopathology, physical examination, laboratory tests, electrocardiogram and concomitant treatment were assessed. Randomization occurred not before 3 weeks post-nephrectomy \\& not after 12 weeks post-nephrectomy.","recruitmentDetails":"Of 674 enrolled participants (615 in global cohort and 59 in china cohort), the results presented refers to the study conducted on 615 (intent-to-treat population) in 21 countries and were randomized to sunitinib and placebo for 9 cycles (1 cycle=42 days)."}